Bifidobacterium infantis 35624

Originally named Bifidobacterium infantis 35624, now reclassified under Bifidobacterium longum subsp. infantis 35624.

Clinical Efficacy

Widely recognized for its targeted efficacy in managing Irritable Bowel Syndrome (IBS) symptoms, including bloating, gas, and irregular bowel movements.